

DAFTAR PUSTAKA

- Adhikari, S., Meng, S., Wu, YJ. *et al.* 2020. *Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review*. Infect Dis Poverty 9, 29. <https://link.springer.com/article/10.1186/s40249-020-00646-x>
- AHA (American Heart Association). 2017. *Hypertension: The Silent Killer: Updated JNC-8 Guideline Recommendations*. Alabama Pharmacy Association. <https://doi.org/0178-0000-15-104-H01-P> (5 Juni 2021).
- Aripin *et al.* 2015. *Faktor Risiko Kejadian Hipertensi Pada Orang Dewasa Di Banyuwangi*. Public Health and Preventive Medicine Archive (PHPMA). Volume 3 (6): 112-118.
- Azwar MK, Setiati S, Rizka A, Fitriana I, Saldi SRF, Safitri ED. 2020. *Clinical Profile of Elderly Patients with COVID-19 hospitalised in Indonesia's National General Hospital*. Acta Med Indones. ;52(3):199-205. PMID: 33020331
- Bakris, George L., dan Matthew J. Sorrentino. 2018. *A Companion to Braunwald's Heart Disease*, 3rd ed. Philadelphia: 3-49.
- Bandiyah. 2009. *Lanjut Usia dan Keperawatan Genoritik*. Nuha Medika. Yogyakarta.
- Barus OP dan Anton Tehja. 2021. *Prediksi Kesembuhan Pasien Covid-19 Di Indonesia Melalui Terapi Menggunakan Metode Naïve Bayes*. Information System Development. UPH. Medan
- Burhan, Erlina *et al.* 2020. *Protokol Tatalaksana COVID-19*. PDPI. Jakarta. Vol 55. doi:10.1331/JAPhA.2015.14093
- BPOM RI. 2014. *Informatorium Obat Nasional Indonesia (IONI)*. Pusat Informasi Obat Nasional. <http://pionas.pom.go.id/ioni>
- Bwire GM. 2020. *Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women?* [published online ahead of print, 2020 Jun 4]. SN Compr Clin Med. 1-3. doi:10.1007/s42399-020-00341-w
- Gugus Tugas COVID-19. (2020). *Peta Sebaran | Gugus Tugas Percepatan Penanganan ETET-19*. <https://covid19.go.id/peta-sebaran> (5 Juni 2021).

- Darmadi, Hamid. 2011. *Metode Penelitian Pendidikan*. Alfabeta. Bandung.
- Darmojo, Boedhi. 2010. *Teori Proses Menua dalam Hadi Martono dan Kris Pranarka*. Ed. Buku Ajar Boedhi Darmojo Geriatri (Ilmu Kesehatan Lanjut Usia). Balai penerbit FKUI. Jakarta.
- Depkes RI, 2005. *Indikator Kinerja Rumah Sakit*. Direktorat Jendral Pelayanan Medik. Jakarta
- Depkes RI. 2006. *Pharmaceutical Care untuk Hipertensi*. Departemen Kesehatan RI. Jakarta.
- Dipiro, et al. 2008. *Pharmacotherapy Handbook Seventh Edition*. McGraw-Hill Company. USA.
- Doremalen, N et al. 2020. *Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1*. New England Journal of Medicine, 382(16), 1564-1567.
- European Society of Cardiology. 2021. *ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up*. European Heart Journal 00, 1–45. doi: 10.1093/eurheartj/ehab697
- Fajgenbaum DC, June CH. 2020. *Cytokine Storm*. N Engl J Med. 383(23):2255-2273. doi: 10.1056/NEJMra2026131
- Fehr AR, Perlman S. 2015. *Coronavirus: An Overview of Their Replication and Pathogenesis*. Methods Mol Biol. 2015. 1282: 1–5.
- Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, Ridolfo AL, Rizzardini G, Antinori S, Galli M. 2020. *Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study*. Clin Infect Dis. Jul 28;71(15):889-890. doi: [10.1093/cid/ciaa330](https://doi.org/10.1093/cid/ciaa330)
- Guan W, Zheng-yi Ni, Yu Hu et al. 2020. *Clinical Characteristics of Coronavirus Disease 2019 in China*, N Engl J Med, 382, pp. 1708–1720. doi: 10.1056/NEJMoa2002032.
- Hidayat, S. S. et al. 2015. *Panduan Penulisan Skripsi Sarjana, Edisi Revisi – Juli 2015*. Fakultas Psikologi Universitas Kristen Maranatha. Bandung.

- Huang C, Yeming Wang, Xingwang Li et al. 2020. *Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China*. The Lancet. doi: [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5)
- Huffman, EK. 1994. *Health Information Management*. Physician Record. Company Berwyn. Illinois. USA
- Hosizah dan Yati Maryati. 2018. *Sistem Informasi Kesehatan II*. Pusat Pendidikan Sumber Daya Manusia Kesehatan. Jakarta
- Ikawati, Zllies. 2020. *Mengenal Reseptor ACE2, “Pintu Masuk” Virus Covid-19*. Fakultas Farmasi Universitas Gadjah Mada. <https://farmasi.ugm.ac.id/id/2020/04/06/mengenal-reseptor-ace2-pintu-masuk-virus-covid-19/>
- JNC-8. 2014. *The Eight Report of the Joint National Commite*. Hypertension Guidelines: An In-Depth Guide. Am J Manag Care
- Katzung B. G. 2007. *Basic and Clinical Pharmacology*. 10th ed. McGraw Hill. Boston.
- Kemenkes RI. (2018). *Hasil Utama Riskesdas 2018*. http://www.depkes.go.id/resources/download/infoterkini/materi_rakorpop_2018/Hasil_Riskesdas_2018.pdf (4 Juni 2021).
- Kemenkes RI. 2014. *Pusdatin Hipertensi Infodatin 2014 (Hipertensi): 1-7*. <https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/infodatin-hipertensi-si-pembunuh-senyap.pdf> (5 Juni 2021)
- Kemenkes RI. 2021. *Cara Efektif Cegah Penularan COVID-19 : Pemeriksaan, Pelacakan, Karantina, dan Isolasi*. Kementrian Kesehatan RI. <https://sehatnegeriku.kemkes.go.id/>
- Kemenkes RI. 2021. *Situasi COVID-19*. Kementerian Kesehatan RI. <https://infeksiemerging.kemkes.go.id>
- Kreutz R, Algharably EAE, Azizi M, Dobrowolski P, Guzik T, Januszewicz A, Persu A, Prejbisz A, Riemer TG, Wang JG, Burnier M. 2020. *Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19*. Cardiovasc Res. 116(10):1688-1699. doi: 10.1093/cvr/cvaa097

- Lam KW, Chow KW, Vo J, Hou W, Li H, Richman PS, Mallipattu SK, Skopicki HA, Singer AJ, Duong TQ. 2020. *Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome*. J Infect Dis. 14;222(8):1256-1264. doi: 10.1093/infdis/jiaa447
- Linelejan, Umboh, Wantania. 2020. *Pengaruh penggunaan angiotensin converting enzyme inhibitor (ACEI) dan angiotensin receptor blocker (ARB) pada pasien coronavirus disease 2019 (covid-19) dengan hipertensi*. e-CliniC Volume 9 (1): 104-109
- Lubis, Ismil Khairi, dan Susilawati. 2017. *Analisis Length Of Stay (Los) Berdasarkan Faktor Prediktor Pada Pasien DM Tipe II di RS PKU Muhammadiyah*. Jkesvo (Jurnal Kesehatan Vokasional). Yogyakarta. Vol. 2 No 2, 162.
- Mancia, Fagard, Narkiewicz *et al.* 2013. *ESH/ESC Guidelines For The Management Of Arterial. Hypertension*. Jhypertension. Vol.31 (7).
- Nafrialdi, Gunawan, Setiabudy. 2012. *Farmakologi dan Terapi Edisi ke 5*. FKUI. Jakarta.
- Nurarif, Amin Huda, Kusuma, Hardhi. 2016. *Asuhan Keperawatan Praktis Berdasarkan Penerapan Diagnosa Nanda, Nic, Noc dalam Berbagai Kasus*. Penerbit Mediacion. Yogyakarta.
- Nursalam. 2013. *Metodologi Penelitian Ilmu Keperawatan : Pendekatan Praktis*. Edisi 4. Salemba Medika. Jakarta.
- Pramana, K. D. (2020). *Penatalaksanaan Krisis Hipertensi*. Jurnal Kedokteran, 5(2), 91–96. <https://doi.org/http://dx.doi.org/10.36679/kedokteran.v5i2.243>
- Safitri MM dan Kriswiharsi Kun. 2012. *Analisa Deskriptif Lama Perawatan (Los) Pasien RI Jamkesmas Pada Kasus Penyakit Kanker Payudara (Ca Mammar)* Dengan Tindakan Mastektomi Yang Dirawat Di Rsi Sultan Agung Semarang Tahun 2012. http://eprints.dinus.ac.id/6526/1/jurnal_12622.pdf
- Schiffirin EL, Flack JM, Ito S, Muntner P, Webb RC. 2020. *Hypertension and COVID-19*. Am J Hypertens. 29;33(5):373-374. doi: 10.1093/ajh/hpaa057

- Semenzato L, Botton J, Drouin J, Baricault B, Vabre C, Cuenot F, Penso L, Herlemont P, Sbidian E, Weill A, Dray-Spira R, Zureik M. 2021. *Antihypertensive Drugs and COVID-19 Risk : A Cohort Study of 2 Million Hypertensive Patients*. American Heart Association Journal. 77:833–842. doi: 10.1161/HYPERTENSIONAHA.120.16314
- Suryantoro, Thaha, Hayati *et al.* 2021. Correlation between anti-hypertensive drugs and disease progression among moderate, severe, and critically ill COVID-19 patients in the second referral hospital in Surabaya: A retrospective cohort study. F1000Research. 10:393. <https://doi.org/10.12688/f1000research.51785.2>
- Undang-Undang Nomor 4 Tahun 1965 tentang *Pemberian Bantuan Penghidupan Orang Jompo*. 1965. Jakarta.
- Undang - Undang Republik Indonesia Nomor 13 tahun 1998 tentang *Kesejahteraan Lanjut Usia*. 1998. Jakarta.
- Unger T, Claudio Borghi, Fadi Charchar *et al.* 2020. *International Society of Hypertension Global Hypertension Practice Guidelines*. Vol. 75 no. 6. <https://doi.org/10.1161/HYPERTENSIONAHA.120.15026>
- Wang, Qiang W, Ke Hu. 2020. *A handbook of 2019-nCoV pneumonia control and prevention*. China: Hubei Science and Technology Press. p.33-40.
- Wang, Zhao X, Wei W, Fan W, Gao K, He S, Zhuang X. 2021. *Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients*. BMC Infect Dis. 25;21(1):114. doi: 10.1186/s12879-021-05821-5
- Weber MA, Schiffrin EL, White WB, Mann S *et al.* 2014. *Clinical Practice Guidelines for the Management of Hhypertension in the Community A Statement by the American Society of Hypertension and the International Society of Hhypertension*. The Journal of Clinical Hypertension. Vol. 16 (1). doi: 10.1111/jch.12237
- WHO. 2013. *A global brief on Hypertension - World Health Day 2013*. World Health Organization. <https://doi.org/10.1136/bmj.1.4815.882-a>
- WHO. 2015. *A global brief on hypertension: silent killer*. Global Public Health Crisis. WHO. <https://apps.who.int/iris/handle/10665/79059> 5 Juni 2021

- WHO. 2021. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. interim guidance. <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1> (5 Juni 2021).
- Wu Z, McGoogan JM. 2020. *Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention*. JAMA. 323(13):1239–1242. doi:10.1001/jama.2020.2648
- Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. 2020. *Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis*. Int J Infect Dis. 94:91-95. doi: 10.1016/j.ijid.2020.03.017
- Yan F., Huang F., Xu J. et al. 2021. *Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients*. Cell Discovery 6:77. <https://doi.org/10.1038/s41421-020-00221-6>
- Yogiantoro M. 2006. *Pendekatan Klinis Hipertensi*. Buku Ajar Ilmu Penyakit. Dalam. P. 2259-61. FKUI. Jakarta
- Yulanda G, Rika L. 2017. *Penatalaksanaan Hipertensi Primer*. Fakultas Kedokteran. Volume 6 (1): 25-33
- Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. 2020. *Clinical characteristics of 140 patients infected with SARS- CoV-2 in Wuhan , China*. European Journal of Allergy and Clinical Immunology. pp. 1–12. <https://doi.org/10.1111/all.14238>
- Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, Wang Y. 2020. *Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis*. Int J Infect Dis. 99:47-56. doi: 10.1016/j.ijid.2020.07.029